Systematic Reviews/Meta-Analysis
Tuesday, November 14, 2023
08:30 AM–10:00 AM
Abstract
Background: Due to the lack of evaluation of its efficacy and safety, we reviewed the role of BAM/ETE during the SARS-CoV-2 epidemic systematically.
Methods: Pubmed, Embase, and Cochrane databases from inception to January 20, 2023 were searched. RCTs and controlled clinical trials (CTs) were included.The quality were assessed by Cochrane Handbook, the Jadad and Newcastle Ottawa scale. The systematic review was conducted via Revman 5.4 and STATA 12.
Results: A total of 10 trials (5 RCTs and 5 CTs) and 15139 adult patients with mild to moderate disease were included. The quality of trials is acceptable,but publication bias exists.
Compared with placebo, the odds of COVID-19-related hospitalization, emergency department visit, and death were lower in BAM/ETE group(pooled RR = 0.27, 95% CI [0.16-0.45]),with good safety profile. The trial sequential analysis suggested this result was stable. The differences of common ADEs odds were not found between BAM/ETE and placebo via Chi-square test.
In RCTs, BAM/ETE was as effective as Casirivimab/Imdevimab (CAS/IMD) on hospitalization and all-cause mortality. But in CTs, it was associated with higher hospitalization rate.The study type was an important source of heterogeneity of hospitalization (P=0.034) via meta-regression analysis. The incompatibility of patients was considered as an important factor.
In the case of safety profile, BAM/ETE was comparable to the other monoclonal antibodies.
In subgroup analysis of different virus strains, the efficacy of BAM/ETE was similar to CAS/IMD and Sotrovimab.
Discussion: In general, BAM/ETE is effective and safe analogous to CAS/IMD and SOT. However, new well-designed trials (especially RCTs) should be conducted. In addition, more confirmation should be provided on whether it is effective to Omicron in vivo. Thus, the research of BAM/ETE should not be interrupted, but enter a new stage with the coordination of an international institution which can control the trial homogeneity among various trials to save research resources.
Other: No funding supported
Presenting Author
Yu Wang MDMianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, Chin
Authors
Zhuqing Meng MD
Mianyang Fulin Hospital, Mianyang, Sichuan, China,
Guirong Xiao MD
West China Hospital,Sichuan University,Chengdu,Sichuan, China,
Xiaowen Xu MD
Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, Chin
Linlin Zhao MD
Sichuan Science City Hospital, Mianyang, Sichuan, China
Su Zhou MD
Sichuan GEM Flower Hospital, Chengdu, Sichuan, China,